COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 57 of 359 for:    ASPIRIN AND clopidogrel AND Purinergic Antagonists

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01823510
Recruitment Status : Completed
First Posted : April 4, 2013
Results First Posted : September 1, 2017
Last Update Posted : December 8, 2017
Information provided by (Responsible Party):
Juan J Badimon, Icahn School of Medicine at Mount Sinai

Brief Summary:
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.

Condition or disease Intervention/treatment Phase
Type-2 Diabetes Mellitus Coronary Artery Disease Drug: Ticagrelor + Aspirin Drug: Clopidogrel + Aspirin Phase 4

Detailed Description:

The rising prevalence of diabetes mellitus and its associated cardiovascular complications present a major burden to healthcare providers worldwide. Cardiovascular mortality is much higher among subjects with Type 2 Diabetes Mellitus (T2DM). Increased platelet reactivity is considered a potential link between the two diseases. Thus, given the higher blood thrombogenicity of T2DM with CAD, the availability of more potent antiplatelet drugs should be associated with improvements in the prevention of cardiovascular events in the diabetic populations. Ticagrelor has been shown to possess a faster onset of action and more potency than clopidogrel. Furthermore, the PLATO has shown that these characteristics results in a significant reduction in Cardiovascular events and even death as compared with Clopidogrel.

We plan to compare the antithrombotic activity of ticagrelor versus clopidogrel in T2DM patients using a cross-over study design. Each participant will be randomly assigned to receive ticagrelor/clopidogrel + aspirin as a loading dose followed by 5-7 days of daily maintenance dosing. After a washout period of 1-2 weeks, each participant will receive the second treatment (clopidogrel/ticagrelor + aspirin) again as a loading dose followed by 5-7 days of daily dosing. Platelet function will be tested at pre-treatment baseline, two post-dose time-points on the day of loading dose, and one time-point after the last maintenance dose on day 5-7. Platelet testing will be carried out using the following methodologies:

  1. Badimon Perfusion Chamber: an ex-vivo model of thrombosis that has been extensively utilized for evaluation of antithrombotic or prothrombotic effects under various pathological states. The model involves native blood perfusing over a thrombogenic substrate, triggering thrombus formation that can be measured by planimetry.
  2. Platelet Aggregation - Multiplate Analyzer.
  3. Platelet Aggregation - VerifyNow P2Y12 assay.
  4. Vasodilator-Stimulated Phosphoprotein (VASP).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients
Study Start Date : July 2013
Actual Primary Completion Date : May 10, 2016
Actual Study Completion Date : May 10, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ticagrelor + Aspirin
Loading-dose plus daily-dosing for 5-7 days.
Drug: Ticagrelor + Aspirin
Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
Other Names:
  • Brilinta (ticagrelor)
  • Aspirin (ASA)

Active Comparator: Clopidogrel + Aspirin
Loading-dose plus daily-dosing for 5-7 days.
Drug: Clopidogrel + Aspirin
Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
Other Names:
  • Plavix (clopidogrel)
  • Aspirin (ASA)

Primary Outcome Measures :
  1. Thrombus Formation [ Time Frame: up to 7 days ]
    Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis).

Secondary Outcome Measures :
  1. Platelet Reactivity [ Time Frame: up to 7 days ]
    Platelet reactivity by Multiplate Analyzer

  2. P2Y12 Reaction Unit (PRU) [ Time Frame: up to 7 days ]
    Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow

  3. Platelet Reactivity Index (PRI) [ Time Frame: up to 7 days ]
    Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic therapy or both.
  • Have not had thienopyridine therapy for at least 30 days before the study.
  • Are of legal age (at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent.
  • For women of child-bearing potential only test negative for pregnancy at the time of enrollment.

Exclusion Criteria:

  • Have a defined need for thienopyridine therapy.
  • Subjects within ≤30 days of coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).
  • Known glycosylated hemoglobin (HbA1c) ≥10 mg/dL within last 3 months prior to study entry.
  • Have received fibrinolytic therapy <48 hours prior to randomization.
  • Have active internal bleeding or history of bleeding diathesis.
  • Have clinical findings that are, in the judgment of the investigator, associated with an increased risk of bleeding.
  • Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or intracranial neoplasm, arteriovenous malformation, or aneurysm.
  • Have an International Normalized Ratio (INR) known to be >1.5 within 1 week of study entry.
  • Have a known platelet count of <100,000/mm3 within 1 week of study entry.
  • Have known anemia (hemoglobin [Hgb] <10 gm/dL) within 1 week of study entry.
  • Are receiving or will receive oral anticoagulation or other antiplatelet therapy (other than ASA) that cannot be safely discontinued for the duration of the trial.
  • Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be discontinued.
  • Have a concomitant medical illness that in the opinion of the investigator may interfere with or prevent completion in this study.
  • Have known severe hepatic dysfunction (e.g., cirrhosis or portal hypertension).
  • Have a history of intolerance or allergy to ASA or approved thienopyridines (ticlopidine or clopidogrel).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01823510

Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Juan J Badimon
Layout table for investigator information
Principal Investigator: Juan J Badimon, PhD Icahn School of Medicine at Mount Sinai
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Juan J Badimon, Professor, Icahn School of Medicine at Mount Sinai Identifier: NCT01823510    
Other Study ID Numbers: GCO 13-0208
First Posted: April 4, 2013    Key Record Dates
Results First Posted: September 1, 2017
Last Update Posted: December 8, 2017
Last Verified: December 2017
Keywords provided by Juan J Badimon, Icahn School of Medicine at Mount Sinai:
Coronary Artery Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors